ZENYF - ZENYF STOCK NEWS

ZEN Graphene Solutions Ltd. (TSXV:ZEN, OTC PINK:ZENYF) announced successful inhalation safety testing results for its ZENGuard^TM-enhanced surgical masks. Conducted by NanoSafe Inc., tests confirmed no graphene release during simulated inhalation rates. This data has been submitted to Health Canada, which is reviewing the application as a priority, with a decision expected soon. CEO Greg Fenton expressed optimism about the commercial viability of ZENGuard^TM, aiming to differentiate the product in the PPE market and enhance protection for users.

ZEN Graphene Solutions Ltd. (TSXV:ZEN, OTC PINK:ZENYF) announced a breakthrough in developing a stable diesel fuel additive that improves diesel fuel performance by up to 10%. A provisional patent has been filed for this graphene-based technology. CEO Greg Fenton highlighted the potential in addressing global diesel fuel emissions, with the market estimated near $1 trillion. The company is pursuing partnerships and funding to expedite commercialization. Key testing occurred at Conestoga College, showcasing versatility for diesel, biodiesel, and potential applications in gasoline and aviation fuels.

ZEN Graphene Solutions Ltd. (OTC PINK: ZENYF) has announced the initiation of a Good Laboratory Practice (GLP) compliant safety study for its graphene-based compound, following successful tests against C. Difficile at the University of Manitoba. Conducted by Nucro-Technics, the 14-day study targets infections including Vancomycin Resistant Enterococcus (VRE) and is expected to take around four months. If successful, ZEN plans to move into phase 1 human trials later in the year. CEO Greg Fenton emphasizes the compound’s potential as a treatment for challenging infections, addressing significant health and financial impacts.

ZEN Graphene Solutions Ltd. (TSX.V:ZEN)(OTC PINK:ZENYF) has provided an update on its recent activities. Key points include the submission of additional information to Health Canada regarding ZENGuard^tm, a new trademark for its antimicrobial graphene-based coating, and successful safety testing confirming no skin irritation. ZEN is committed to ramping up production capacity, targeting 32 million masks by June and 800 million by November 2021. The company has also completed a private placement, securing approximately $5.3 million in liquidity, and issued stock options to employees and consultants.

ZEN Graphene Solutions Ltd. (ZENYF) supports Health Canada's regulatory measures regarding graphene masks, emphasizing their safe biocidal coatings tested by Nucro-Technics. Their partner, Trebor Rx Corp., has successfully met Canadian standards for surgical masks. ZEN also explores pharmaceutical applications for its graphene formulation, with positive initial safety results in animal testing. CEO Greg Fenton stresses their commitment to safety and public health in developing effective technologies. ZEN is positioned to deliver innovative solutions in the graphene market, asserting the importance of validated and safe products for front-line workers.

ZEN Graphene Solutions Ltd. has successfully upsized its non-brokered private placement to 2,000,000 units at CDN$2.50 per unit, aiming for gross proceeds of up to CDN$5,000,000, due to strong demand. The offering is now closed to new interest, with closure expected by April 6, 2021. The funds will support capital and operating expenses related to the company's biocidal coating production and expand its intellectual property in graphene technology. The offering's completion is pending TSX Venture Exchange approval.

ZEN Graphene Solutions Ltd. has increased its non-brokered private placement offering to 1,600,000 units at CDN$2.50 each, aiming for gross proceeds of up to CDN$4,000,000. The offering closes April 1, 2021. Each unit includes a common share and a warrant, exercisable at CDN$3.00 for 24 months. The company plans to use proceeds for capital expenditures and operational expenses supporting its biocidal coating production. The offering is subject to TSX Venture Exchange approval and related party transactions may occur, but they will be exempt from formal valuation requirements.

ZEN Graphene Solutions Ltd. has announced an increase in its non-brokered private placement to up to 1,400,000 units at CDN$2.50 per unit, aiming for gross proceeds of up to CDN$3,000,000. Each unit consists of one common share and one-half warrant, exercisable at CDN$3.00 for 24 months. The offering is available to existing shareholders under the Existing Security Holder Exemption. Funds will support capital expenditures, operating expenses for biocidal coating production, and further investment in intellectual property. Closing is subject to TSX Venture Exchange approval.

ZEN Graphene Solutions Ltd. has announced a non-brokered private placement offering of units to raise up to $2 million at $2.50 per unit, subject to TSX Venture Exchange approval. Each unit consists of one common share and one-half warrant, with full warrants exercisable at $3.00 for 24 months. Proceeds will fund capital expenditures, operating expenses, and graphene research. All securities are subject to a four-month hold period, and the offering does not involve U.S. registration.